DePuy Synthes Spine gains exclusive rights to launch LifeNet Health’s cellular allograft product

107

DePuy Synthes Spine and DePuy Synthes Biomaterials, divisions of DePuy Orthopaedics, have announced that they have entered into an exclusive worldwide representative agreement for the marketing and promotion of a new cellular allograft product developed by LifeNet Health.

According to the press release, the representative agreement marks the entry of DePuy Synthes Spine, in collaboration with DePuy Synthes Biomaterials, into cellular allografts for spinal fusion, one of the fastest growing segments of spine, and bolsters the group’s portfolio of biomaterial solutions for the treatment of spinal and orthopaedic pathologies. 

“Our clinical, sales and marketing teams are energised by this new collaboration that will offer clinicians a new technology for treating spine patients,” says Max Reinhardt, worldwide president, DePuy Synthes Spine. “We are excited to collaborate with LifeNet Health and our colleagues in DePuy Synthes Biomaterials to enhance our product offering with biomaterials that complement and augment our spine portfolio.”

The representative agreement adds cellular allograft products to the company’s growing portfolio of allograft implants.